Congressional committees working on the reauthorization of FDA user fees, including a fee for the health reform-created biosimilars review pathway, could begin marking up bills the last week in April, sources said, with the Senate health committee planning to convene a markup the week of April 23. A bipartisan draft is expected from the House Energy and Commerce Committee in the coming weeks, a source said, noting that both chambers still have to address gaps in their legislative measures.
Forgot password?
Sign up today and your first download is free.
REGISTER
User Fees
April 04, 2012 |
Daily News
Draft drug reform legislation released by the Senate health committee Wednesday (April 4) instructs FDA to release long-awaited social media guidance, with the bill also including previously introduced measures codifying the accelerated approval process, creating a new breakthrough drug designation to speed up development of promising medications and expanding the agency's use of experts for advice on rare diseases.
Pages
© 2002-2019. Inside Washington Publishers